Clinical trials: Childhood Lymphoblastic Lymphoma
Leukemia
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia.
- Trial name
- NCT00002704
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00381680
- Testing
- vincristine sulfate, prednisone, doxorubicin hydrochloride
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- Children's Oncology Group
L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Conditions
- L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00049569
- Testing
- cytarabine, methotrexate, vincristine sulfate
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This clinical trial studies fludarabine phosphate, low-dose total body irradiation, and donor stem cell transplant in treating patients with hematologic malignancies or kidney cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00005799
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 7 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL)
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies.
- Conditions
- Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02091245
- Testing
- KPT-330
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- Interfant06 (NCT00550992)
- Testing
- anti-thymocyte globulin, asparaginase, busulfan
- Where
- 13 sites in United States, Austria and 7 more
- Volunteers
- 445 people
- Sponsor
- Dutch Childhood Oncology Group
Leukemia
Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer PURPOSE: This laboratory study is looking into RNA in samples…
- Trial name
- NCT01626183
- Testing
- RNA analysis, proteomic profiling, laboratory biomarker analysis
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Leukemia
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having…
- Trial name
- NCT00020670
- Testing
- CD 40
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Brain Cancer, Acute Lymphoblastic Leukemia
Urban Environmental Exposures and Childhood Cancer
The Environmental Protection Agency has recognized that organophosphorus pesticides require close regulation and continued monitoring for human health effects and some (e.g chlorpyrifos) have been phased-out from the consumer…
- Trial name
- NCT00505141
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Georgetown University
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004105
- Testing
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Where
- United States
- Sponsor
- NYU Langone Health
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors.
- Conditions
- Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma
- Trial name
- NCT00093821
- Testing
- tanespimycin, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphocytic, Acute, L1
Osteoporosis in Children With ALL
Hypothesis: Pediatric patients with acute lymphoblastic leukemia, treated with chronic glucocorticoids as a part of the leukemia treatment protocol, will have an increased incidence and severity of osteoporosis.
- Trial name
- NCT00330538
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Mercy Hospital Kansas City
Leukemia, Myelodysplastic Syndromes
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00376480
- Testing
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
- Trial name
- NCT07071051
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Leukemia
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant may prevent the recurrence of Philadelphia…
- Trial name
- NCT00244829
- Testing
- imatinib mesylate, adjuvant therapy
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Trial name
- NCT00002941
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 69 people
- Sponsor
- Children's Oncology Group
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)